Fig. 5
From: Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential
Inhibitors of inflammasomes and related pathways. This figure highlights various inhibitors that specifically target key components of inflammasomes activation, including NLRP1, NLRP3, AIM2, ASC, caspase-1, interleukin-1β, interleukin-18, and GSDMD. These inhibitors by effectively blocking inflammasome activation, suppress pyroptosis and the release of pro-inflammatory cytokines, offering potential therapeutic strategies for inflammation-driven cancer and other diseases